2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative

Annals of the Rheumatic Diseases

Volumn 75, Issue 3, 2016, Pages 481-489

  Ravelli, Angelo ^a,b   Minoia, Francesca ^b   Davì, Sergio ^b   Horne, AnnaCarin ^c   Bovis, Francesca ^b   Pistorio, Angela ^b   Aricò, Maurizio ^d   Avcin, Tadej ^e   Behrens, Edward M ^f   De Benedetti, Fabrizio ^g   Filipovic, Lisa ^h   Grom, Alexei A ^h   Henter, Jan Inge ^c   Ilowite, Norman T ⁱ   Jordan, Michael B ^h   Khubchandani, Raju ^j   Kitoh, Toshiyuki ^k   Lehmberg, Kai ^l   Lovell, Daniel J ^h   Miettunen, Paivi ^m   Nichols, Kim E ⁿ   Ozen, Seza ^o   Schmid, Jana Pachlopnik ^p   Ramanan, Athimalaipet V ^q   Russo, Ricardo ^r   Schneider, Rayfel ^s   Sterba, Gary ^t   Uziel, Yosef ^u   Wallace, Carol ^v   Wouters, Carine ^w   Wulffraat, Nico ^x   Demirkaya, Erkan ^y   Brunner, Hermine I ^h   Martini, Alberto ^a   Ruperto, Nicolino ^b   Cron, Randy Q ^z   more..

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Azienda sanitaria provinciale (ASP)   (Italy)

^e UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^j JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^k AICHI MEDICAL UNIVERSITY   (Japan)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^o HACETTEPE UNIVERSITY   (Turkey)

^p UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^q BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^r HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^s HOSPITAL FOR SICK CHILDREN   (Canada)

^t MOUNT SINAI MEDICAL CENTER   (United States)

^u MEIR MEDICAL CENTER   (Israel)

^v UNIVERSITY OF WASHINGTON   (United States)

^w UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^x UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^y GULHANE SCHOOL OF MEDICINE   (Turkey)

^z UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; CONSENSUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; HUMAN; LABORATORY TEST; MACROPHAGE ACTIVATION SYNDROME; MEDICAL EXPERT; PATIENT INFORMATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; VALIDATION STUDY; CHILD; CLASSIFICATION; COMPLICATION; CONSENSUS DEVELOPMENT; DELPHI STUDY; EUROPE; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL SOCIETY; REPRODUCIBILITY; RHEUMATOLOGY; STATISTICAL MODEL; UNITED STATES;

ARTHRITIS, JUVENILE; CHILD; DELPHI TECHNIQUE; EUROPE; HUMANS; LOGISTIC MODELS; MACROPHAGE ACTIVATION SYNDROME; REPRODUCIBILITY OF RESULTS; RHEUMATOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84960193018     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208982     Document Type: Article

References (39)

1. Prieur AM, Stephan JL. Macrophage activation syndrome in rheumatic diseases in children. Rev Rhum Ed Fr 1994;61:447-51. In French.
2. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996;129:630-2.
3. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
4. Ravelli A, Martini A. Macrophage activation syndrome. In: Lehman TH, Cimaz R, eds. Pediatric rheumatology. Amsterdam: Elsevier, 2008:55-63.
5. Parodi A, Davi S, Pringe AB, et al., for the Lupus Working Group of the Paediatric Rheumatology European Society. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009;60:3388-99.
6. Avcin T, Tse SM, Schneider R, et al. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006;148:683-6.
7. Kumar S, Vaidyanathan B, Gayathri S, et al. Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol Int 2013;33:1065-9.
8. Simonini G, Pagnini I, Innocenti L, et al. Macrophage activation syndrome/hemophagocytic lymphohistiocytosis and Kawasaki disease [letter]. Pediatr Blood Cancer 2010;55:592.
9. Rigante D, Capoluongo E, Bertoni B, et al. First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2007;56:658-61.
10. Rossi-Semerano L, Hermeziu B, Fabre M, et al. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care Res (Hoboken) 2011;63:780-3.
11. Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012;13:289-98.
12. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010;22:561-6.
13. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52.
14. Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007;34:1133-8.
15. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.
16. Minoia F, Davi S, Horne A, et al., on behalf of the Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66:3160-9.
17. Minoia F, Davi S, Horne A, et al., Pediatric Rheumatology International Trials Organization, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology Collaborative Study Group, Histiocyte Society. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol 2015;42:994-1001.
18. Bode SF, Lehmberg K, Maul-Pavicic A, et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther 2012;14:213.
19. Arico M, Janka G, Fischer A, et al., FHL Study Group of the Histiocyte Society. Hemophagocytic lymphohistiocytosis: report of 122 children from the International Registry. Leukemia 1996;10:197-203.
20. Ho C, Yao X, Tian L, et al. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol 2014;141:62-71.
21. Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol 2014;26:562-9.
22. Zhang M, Behrens EM, Atkinson TP, et al. Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep 2014;16:439.
23. Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014;66:3486-95.
24. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.
25. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604.
26. Davi S, Minoia F, Pistorio A, et al., on behalf of the Paediatric Rheumatology International Trials Organisation, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014;66:2871-80.
27. Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011;38:764-8.
28. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007;19:477-81.
29. Stephan J, Kone-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001;40:1285-92.
30. Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand 1986;75:64-8.
31. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
32. Ravelli A, Minoia F, Davi S, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open 2015;1:e000161.
33. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55.
34. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
35. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
36. Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol 2013;40:761-7.
37. Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012;58:287-94.
38. De Benedetti F, Scheider R, Weitzman S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab[abstract]. Pediatr Blood Cancer 2015;62(S1):S5.
39. Grom AA, Ilowite NT, Pascual V, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 2016;68:218-28.